713100-30-2

Basic information

• Product Name: 2-Propanol, 1-amino-3-(phenylmethoxy)-, (2S)-
• CAS NO: 713100-30-2
• Molecular Formula: C10H15NO2
• Molecular Weight: 181.235
• Mol File: 713100-30-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-Propanol, 1-amino-3-(phenylmethoxy)-, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propanol, 1-amino-3-(phenylmethoxy)-, (2S)-(713100-30-2)
• EPA Substance Registry System: 2-Propanol, 1-amino-3-(phenylmethoxy)-, (2S)-(713100-30-2)

Safety Data

• Hazardous Substances Data: 713100-30-2(Hazardous Substances Data)

Upstream product

• 23214-66-6 (R)-3-(benzyloxy)-2-hydroxypropyl 4-methylbenzene sulfonate 
• 2930-05-4 (S)-benzyl glycidyl ether 
• 100-51-6 benzyl alcohol 
• 17325-85-8 (2S)-3-(benzyloxy)propane-1,2-diol 

Downstream Products

• 1262536-13-9 C₆₁H₁₁₈N₂O₁₃Si₃ 
• 1262536-17-3 C₆₁H₁₁₆N₂O₁₂Si₃ 
• 497831-41-1 C₄₃H₇₄N₂O₁₂ 
• 497831-56-8 C₄₄H₇₆N₂O₁₂ 

Relevant articles and documents

BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY

Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS

Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.

Synthesis and antibacterial activity of a novel class of 15-membered macrolide antibiotics, "11a-Azalides"

An efficient method for the reconstruction of the 9-dihydroerythromycin A macrolactone skeleton has been established. The key steps are oxidative cleavage at the 11,12-position and reconstruction after insertion of an appropriate functionalized amino alcohol. Novel 15-membered macrolides, we named as "11a-azalides", were synthesized based on the above methodology and evaluated for their antibacterial activity. Among them, (13R)-benzyloxymethyl- 11a-azalide showed the most potent Streptococcus pneumoniae activity, with improved activity against a representative erythromycin-resistant strain compared to clarithromycin (CAM).